Sangamo BioSciences, Inc. announced today the presentation of new data from its ongoing Phase 2 clinical trial to evaluate a single infusion of Sangamo's novel ZFP Therapeutic^A , SB-728-T, for the treatment of HIV/AIDS.
http://www.benzinga.com/news/13/09/3910028/sangamo-biosciences-announces-data-from-trial-of-sb-728-t-shows-sustained-cut-of-
http://www.benzinga.com/news/13/09/3910028/sangamo-biosciences-announces-data-from-trial-of-sb-728-t-shows-sustained-cut-of-
No comments:
Post a Comment